Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent

MDA-LDL was associated with future cardiac events in patients with stable angina that underwent lipid-lowering therapy after DES-PCI.